Comparison of national/regional diabetes guidelines for the management of blood glucose control in non-western countries

Diabetes Therapy

Volumn 4, Issue 1, 2013, Pages 91-102

  Home, Philip ^a   Haddad, Jihad ^b   Latif, Zafar Ahmed ^c   Soewondo, Pradana ^d   Benabbas, Youcef ^e   Litwak, Leon ^f   Guler, Serdar ^g   Chen, Jian Wen ^h   Zilov, Alexey ⁱ  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Division of Endocrinology Prince Hamazah Hospital   (Jordan)

^c Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders   (Bangladesh)

^d UNIVERSITY OF INDONESIA   (Indonesia)

^e University Hospital of Constantine ^*  (Algeria)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h Novo Nordisk FemCare AG   (Switzerland)

ⁱ PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Diabetes; Fasting plasma glucose; Guidelines; Local care; Non western countries; Post prandial glucose; Type 1 diabetes; Type 2 diabetes

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; SHORT ACTING INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD GLUCOSE MONITORING; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 84897382333     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0022-2     Document Type: Article

References (32)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21.
2. International Diabetes Federation. The IDF Diabetes Atlas 5th Edition: A summary of the figures and key findings. Available at: http://www.idf.org/diabetesatlas/downloads. Accessed 30 Aug 2012.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
4. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:293-301.
5. Huizinga MM, Rothman RL. Addressing the diabetes pandemic: a comprehensive approach. Indian J Med Res. 2006;124:481-4.
6. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370:1929-38.
7. Arredondo A, Zuniga A. Economic consequences of epidemiological changes in diabetes in middleincome countries: the Mexican case. Diabetes Care. 2004;27:104-9.
8. Unwin N, Alberti KG. Chronic non-communicable diseases. Ann Trop Med Parasitol. 2006;100:455-64.
9. International Diabetes Federation. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23:579-93.
10. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Available at: http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 10 Jun 2012.
11. Ryden L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28: 88-136.
12. Nathan DM, Buse JB, Davidson MB, et al. European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
13. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(Suppl 1):S11-61.
14. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(Suppl 1):S11-61.
15. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(Suppl 1):S11-63.
16. International Diabetes Federation Clinical Guidelines Task Force. Global guidelines for type 2 diabetes. Available at: http://www.idf.org/globalguideline-type-2-diabetes-2012. Accessed 5 Dec 2012.
17. Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association; European Association for the Study of Diabetes, et al. Management of hyperglycemia in type 2 diabetes: a patientcentered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
18. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11-66.
19. Sloan FA, Bethel MA, Lee PP, Brown DS, Feinglos MN. Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes. Rev Diabet Stud. 2004;1:29-38.
20. Bouldin MJ, Low AK, Blackston JW, et al. Quality of care in diabetes: understanding the guidelines. Am J Med Sci. 2002;324:196-206.
21. Jenssen TG, Tonstad S, Claudi T, Midthjell K, Cooper J. The gap between guidelines and practice in the treatment of type 2 diabetes A nationwide survey in Norway. Diabetes Res Clin Pract. 2008;80:314-20.
22. Puder JJ, Keller U. Quality of diabetes care: problem of patient or doctor adherence? Swiss Med Wkly. 2003;133:530-4.
23. Engelgau MM, Narayan KM, Saaddine JB, Vinicor F. Addressing the burden of diabetes in the 21st century: better care and primary prevention. J Am Soc Nephrol. 2003;14:S88-91.
24. McCraw WM, Kelley PW, Righero AM, Latimer R. Improving compliance with diabetes clinical practice guidelines in military medical treatment facilities. Nurs Res. 2010;59:S66-74.
25. van Bruggen R, Gorter KJ, Stolk RP, Verhoeven RP, Rutten GE. Implementation of locally adapted guidelines on type 2 diabetes. Fam Pract. 2008;25:430-7.
26. Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care. 2007;13(Suppl 2):S47-54.
27. VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm. 2008;14:363-80.
28. Wasikowa RB, Basiak A. Progress in the treatment of diabetes type 1 and 2. Pediatr Endocrinol Diabetes Metab. 2007;13:47-51.
29. International Society for Pediatrics and Adolescent Diabetes. Clinical Practice Consensus Guidelines. Available at: http://www.ispad.org/FileCenter.html?CategoryID=5. Accessed 17 Jan 2013.
30. Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010;33:1895-902.
31. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med. 2010;103:139-47.
32. Pathan MF, Sahay RK, Zargar AH, et al. South Asian Consensus Guideline: use of insulin in diabetes during Ramadan. Indian J Endocrinol Metab. 2012;16:499-502.